<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00318162</url>
  </required_header>
  <id_info>
    <org_study_id>PDDLDN-HMO-CTIL</org_study_id>
    <nct_id>NCT00318162</nct_id>
  </id_info>
  <brief_title>Trial of Low-Dose Naltrexone for Children With Pervasive Developmental Disorder (PDD)</brief_title>
  <official_title>Randomized Double-Blind Trial of Low-Dose Naltrexone for Children With PDD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hadassah Medical Organization</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Jerusalem Institute for Child Development</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hadassah Medical Organization</source>
  <brief_summary>
    <textblock>
      This study will examine the effects of low-dose naltrexone (LDN) on children with autistic
      spectrum disorders. The investigators hope to show a positive effect on social functioning
      and language.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Fifty children aged three to six years will be recruited for the study. They will be randomly
      assigned to receive either LDN or placebo for two months after which the treatment groups
      will be switched over. Assessments of functioning will be obtained from a video-taped play
      session, and by parent and teacher questionnaires at baseline, after two months and after
      four months.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>play observation</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Autism Behavior Checklist (ABC) questionnaire</measure>
  </primary_outcome>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Pervasive Developmental Disorder</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>low dose naltrexone</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of PDD
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>6 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David S Wilensky, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jerusalem Institute for Child Development</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>David S Wilensky, MD</last_name>
    <phone>97227828142</phone>
    <email>davidvil@012.net.il</email>
  </overall_contact>
  <location>
    <facility>
      <name>Jerusalem Institute for Child Development</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>April 2006</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 25, 2006</study_first_submitted>
  <study_first_submitted_qc>April 25, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 26, 2006</study_first_posted>
  <last_update_submitted>May 2, 2006</last_update_submitted>
  <last_update_submitted_qc>May 2, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 3, 2006</last_update_posted>
  <keyword>autism</keyword>
  <keyword>PDD</keyword>
  <keyword>LDN</keyword>
  <keyword>naltrexone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Developmental Disabilities</mesh_term>
    <mesh_term>Autism Spectrum Disorder</mesh_term>
    <mesh_term>Child Development Disorders, Pervasive</mesh_term>
    <mesh_term>Autistic Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Naltrexone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

